

Hemostemix's stem cell therapy pursues 'Your Fountain of Youth'

written by InvestorNews | April 18, 2022

What's a company worth to investors that could improve numerous medical conditions related to ischemia (lack of blood flow) and tissue damage, and potentially [improve the quality of life](#)? It would be hard to put a price on such a company if they could successfully commercialize or license their product or technology.

Today's company, [Hemostemix Inc.](#) (TSXV: HEM | OTCQB: HMTXF | FSE: 2VF0), is having remarkable success, yet due to its early stage has a market cap of only [C\\$19 million](#). That company is developing methods that use our own bodies' stem cells to heal certain diseases. The key diseases of focus for now are those revolving around ischemia, such as heart disease, stroke, and diabetic vascular disease and its complications such as limb loss. Over the next year, there will also be a lot of work done on nerve cell regeneration.

[Hemostemix Inc.](#) is developing 'stem cell therapy' for the treatment of ischemic disease and several other diseases. Hemostemix [owns 91 patents](#) across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell Therapy.

Results to date have been outstanding, as shown in the image below.

Hemostemix summary of the business and ACP-01

ACP-01 is Hemostemix's pioneering first stem cell treatment called angiogenic cell precursor ("ACP"). Hemostemix [states](#): "ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double-blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation. On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract presentation entitled "Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Follow-up" which noted **healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outcomes maintained for up to 4.5 years.**"

Note: Bold emphasis by the author.

With such stunning success, it is little wonder that Hemostemix is very keen to protect their intellectual property.

On February 14, 2022 Hemostemix [announced](#) that they had "been granted International Trademark Registration No. 1624069 for **Your Fountain of Youth**, a registration that is valid for a period of 10 years." Hemostemix further [announced](#) on March 23, 2022 that it had resolved outstanding litigation with a settlement agreement that requires the other parties to return all data and intellectual property in relation to ACP-01 in their possession to Hemostemix.

This is a great outcome for Hemostemix and good news to investors, as the Company believes their ACP-01 intellectual property is incredibly valuable.

Hemostemix has previously published numerous other studies proving the benefit of ACP-01, notably in the treatment of ischemia in various parts of the body. Some examples include [improving ischemic cardiomyopathy patients](#) and [limb ischemia](#)

[patients](#).

Note: NCP stands for Nerve Cell Precursor. CCP stands for Cardiac Cell Precursor. These are cultivated from the patient's own stem cells using Hemostemix's patented technologies.

What's next for Hemostemix?

Apart from further studies, Hemostemix is now looking towards automating production, partnering and commercialization. The goal of improving stem cell production will help lower costs and potentially expand the business. Hemostemix also intends to advance their business development plans including possible licensing of their technology.

To help fund the above, Hemostemix recently announced a [\\$2,750,000 Convertible Debenture offering](#).

Closing remarks

Hemostemix's longer-term goal is to support a higher quality of life for all of us, a veritable "fountain of youth", where we could boost our health yearly with our own stem cells to help repair our bodies.

Hemostemix trades on a market cap of [C\\$19 million](#). Risk remains high due to the early stage, however there is truly blue sky potential if the Company can successfully license or commercialize their products in future years.